Howard Gurney

Has grant

Macquarie University

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Tamoxifen dose escalation (TADE study)

Open Date: 2012-01-01

Close Date: 2014-12-31

Grant: Close

Tamoxifen dose escalation (TADE study)

Open Date: 2012-01-01

Close Date: 2014-12-31

Grant: Close

The timing of androgen deprivation in prostate cancer

Open Date: 2005-01-01

Close Date: 2007-12-31

Grant: Close

The timing of androgen deprivation in prostate cancer

Open Date: 2005-01-01

Close Date: 2007-12-31

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (12)

Matthew Campbell

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Joan Carles

ASSOCIATED PROFESSOR

Senior Lecturer

University of Sydney

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Howard Gurney

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (19)

Psychosocial factors associated with perceived cognitive functioning in prostate cancer survivors: an exploratory cross-sectional analysis

BRCA mutation testing in men with metastatic castration-resistant prostate cancer

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer

Administration of nivolumab plus ipilimumab

Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU)

Avelumab first-line maintenance for advanced urothelial carcinoma

Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma

Avelumab first-line maintenance for advanced urothelial carcinoma

Psychosocial Factors Associated with Cognitive Function in Prostate Cancer Survivors on Hormonal Treatments: A Systematic Review

Prevalence of Australians exposed to potentially cardiotoxic cancer medicines

Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial

Avelumab first-line maintenance therapy for advanced urothelial carcinoma

Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma

Patient-reported outcomes in men with metastatic castration-resistant prostate cancer harboring DNA damage response alterations treated with talazoparib

Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres

Dual-energy x-ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy

Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer

Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region

Collaborators (12)

Matthew Campbell

Joan Carles

martin brown

Stéphane Oudard

Haryana Dhillon

Mathis Grossmann

Heather Francis

Claire M. Vajdic

Kerry Sherman

Jae Lyun Lee

Lauren Julia Brown

Ines Pires da Silva

Make your next move.